West Pharmaceutical stock holds firm after Q2 beat
Published on 08/25/2026 at 13:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
West Pharmaceutical Services (US9523901012) is trading with a $24.87 billion market cap after opening at $353.33, while the latest consensus target stands at $368.08 and the stock carries a 45.24 P/E ratio. Second-quarter 2026 revenue was $872.3 million and adjusted EPS was $2.37, giving investors a fresh read on a business that is still being valued on earnings power.
Q2 figures set the tone
The reported $872.3 million in revenue for the second quarter of 2026 was paired with adjusted EPS of $2.37, and both figures still anchor the current debate over valuation. Revenue and profit are moving in the same direction on the same report card, which helps explain why the market is still treating the shares as a premium name.
The comparison matters: a $368.08 average target leaves the shares with only modest room to that level from the $353.33 opening print, while the 45.24 P/E ratio shows that expectations remain elevated. That mix of a high multiple and a solid quarterly print leaves less room for disappointment than for slower growers.
What the valuation says
West Pharmaceutical is still being judged against its ability to convert specialized packaging demand into durable margins, not just top-line growth. The current beta of 1.15 suggests the stock is only moderately more volatile than the broad market, but the valuation keeps the focus on execution rather than sentiment.
For investors, the key contrast is simple: a second-quarter revenue base of $872.3 million and EPS of $2.37 versus a 45.24 P/E ratio and a $368.08 average target. The stock is not priced like a laggard.
Product line
The company's product set centers on injectable containment and delivery components, including packaging systems used in sterile pharmaceutical applications. That business mix helps explain why quarterly revenue can stay tied to drug-development and manufacturing demand rather than to consumer-cycle swings.
Price and setup
West Pharmaceutical shares opened at $353.33, compared with a consensus target of $368.08 and a market cap of $24.87 billion as of August 25, 2026. The gap between price and target is narrow, so the next move will likely depend more on earnings follow-through than on multiple expansion.
Fact box
Company: West Pharmaceutical Services, Inc.
ISIN: US9523901012
Ticker: WST
Exchange: NYSE
Price (as of August 25, 2026, 9:30 a.m. ET): $353.33 USD
Market cap: $24.87 billion
Sector / Industry: Health Care / Health Care Supplies
Index membership: S&P 500
